$KAPA
- Three ongoing clinical programs
⎼ Phase 2 trial treating Prostate Cancer with NIH grant funding
⎼ Phase 1 trial in treating Non-Small Cell Lung Cancer –Non-dilutive, Donor funded
⎼ Cleared IND for Glioblastoma
Strategic relationship with Cedars-Sinai Medical Center (ranked
#2 hospital nationally in 2022-2023 US News and World Report) drives clinical trial efficiency (Costs and Enrollment), and streamlines therapeutic innovations
Initial clinical development focuses on therapies to overcome cancer drug resistance, derisked with extensive safety studies and biomarker for potential response
Extensive therapies to reverse immune suppression in our pipeline
Extensive IP portfolio valid until 2035 to 2040
Our technologies target a high value, large market - a fast growing $11.3 billion hormone therapy prostate cancer market, $14 billion lung cancer market, and $94 billion immunotherapy market